Trial · NCT04370548
Adverse events106
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 106
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vulvovaginal candidiasis | Infections and infestations | Clindamycin Phosphate Vaginal Gel, 2% | 35 | 203 | 37 |
| other | Vulvovaginal candidiasis | Infections and infestations | Placebo Vaginal Gel (Universal HEC Placebo Gel) | 4 | 103 | 4 |
| other | Anaemia | Blood and lymphatic system disorders | Clindamycin Phosphate Vaginal Gel, 2% | 1 | 203 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Placebo Vaginal Gel (Universal HEC Placebo Gel) | 0 | 103 | 0 |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Clindamycin Phosphate Vaginal Gel, 2% | 1 | 203 | 1 |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Placebo Vaginal Gel (Universal HEC Placebo Gel) | 0 | 103 | 0 |
| other | Ear Pain | Ear and labyrinth disorders | Clindamycin Phosphate Vaginal Gel, 2% | 1 | 203 | 1 |
| other | Ear Pain | Ear and labyrinth disorders | Placebo Vaginal Gel (Universal HEC Placebo Gel) | 0 | 103 | 0 |
| other | Abdominal Pain | Gastrointestinal disorders | Clindamycin Phosphate Vaginal Gel, 2% | 2 | 203 | 2 |
| other | Abdominal Pain | Gastrointestinal disorders | Placebo Vaginal Gel (Universal HEC Placebo Gel) | 2 | 103 | 2 |
| other | Abdominal pain lower | Gastrointestinal disorders | Clindamycin Phosphate Vaginal Gel, 2% | 1 | 203 | 1 |
| other | Abdominal pain lower | Gastrointestinal disorders | Placebo Vaginal Gel (Universal HEC Placebo Gel) | 0 | 103 | 0 |
| other | Constipation | Gastrointestinal disorders | Clindamycin Phosphate Vaginal Gel, 2% | 1 | 203 | 1 |
| other | Constipation | Gastrointestinal disorders | Placebo Vaginal Gel (Universal HEC Placebo Gel) | 0 | 103 | 0 |
| other | Diarrhea | Gastrointestinal disorders | Clindamycin Phosphate Vaginal Gel, 2% | 2 | 203 | 2 |
| other | Diarrhea | Gastrointestinal disorders | Placebo Vaginal Gel (Universal HEC Placebo Gel) | 1 | 103 | 1 |
| other | Pyrexia | General disorders | Clindamycin Phosphate Vaginal Gel, 2% | 1 | 203 | 1 |
| other | Pyrexia | General disorders | Placebo Vaginal Gel (Universal HEC Placebo Gel) | 0 | 103 | 0 |
| other | Bacterial Vaginosis | Infections and infestations | Clindamycin Phosphate Vaginal Gel, 2% | 3 | 203 | 3 |
| other | Bacterial Vaginosis | Infections and infestations | Placebo Vaginal Gel (Universal HEC Placebo Gel) | 3 | 103 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04370548/events